166 filings
Page 2 of 9
8-K
21hx 5lae6yqf7mv3jwv
12 Oct 23
Material Modifications to Rights of Security Holders
4:01pm
8-K
ze2lfvu
18 Sep 23
Departure of Directors or Certain Officers
5:03pm
8-K
bi5 qbsdm6hge
11 Aug 23
T2 Biosystems Announces Second Quarter 2023 Financial Results
4:00pm
8-K
zvlvm8 sogo744dnanse
9 Aug 23
Regulation FD Disclosure
4:10pm
8-K
u964okylq4apxlyjaq
31 Jul 23
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements
9:11am
8-K
b4xco03hywa8qbzv7o6
20 Jul 23
T2 Biosystems Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
8:30am
8-K
edl tvfimn2l97
12 Jul 23
T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results
8:05am
8-K
9sr hgxrg9g
6 Jul 23
Entry into a Material Definitive Agreement
8:08am
8-K
z5oi8ilj6b0cfsz34g
23 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:01pm
8-K
fcngr6kjixhtogms oy
9 Jun 23
Regulation FD Disclosure
8:45am
8-K
kdrzucf
5 Jun 23
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
9:00am
8-K
svt1pntl9r tlvguuft5
30 May 23
T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History
9:01am
8-K
c4o0p4omk16dut9z9
25 May 23
T2 Biosystems Announces First Quarter 2023 Financial Results
4:55pm
8-K
trbguuicm1xth
23 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:13pm
8-K
9yoda ad1bznn0gw7u9
31 Mar 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:00pm
8-K
f60s keah24e99pm
16 Mar 23
T2 Biosystems Announces Fourth Quarter and Full Year 2022 Financial Results
4:01pm
8-K
qutg 0dfi3
16 Feb 23
Other Events
4:17pm
8-K
8v1dkq6zra43h y89q
13 Feb 23
Other Events
4:05pm
8-K
l5zdvq 7k
23 Jan 23
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results
5:11pm
8-K
xtq40i ky
25 Nov 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:01pm